Previous close | 50.03 |
Open | 50.31 |
Bid | 49.80 x 1200 |
Ask | 51.32 x 1800 |
Day's range | 50.17 - 51.01 |
52-week range | 46.93 - 58.10 |
Volume | |
Avg. volume | 2,525,869 |
Market cap | 127.388B |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | 18.42 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.75 (3.42%) |
Ex-dividend date | 26 May 2022 |
1y target est | N/A |
Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma. The approval is based on the pivotal VOYAGE phase 3 trial which enrolled 408 children aged six to 11 years with uncontrolled moderate- to severe asthma. The primary endpoint of the trial was the annualized rate of sev
Today sanofi-aventis Canada Inc. (Sanofi) announced the approval of Libtayo® (cemiplimab) for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease. The approval is based on the Phase 3 EMPOWER-Cervical 1 Study of Cemiplimab in Adults With Cervical Cancer (NCT03257267). The trial, which was the largest-ever randomized clinical trial in advanced cer
BOTHELL, Wash. & PARIS, March 16, 2022--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has o